Introduction 

• The global nucleic acid therapeutics contract manufacturing market is entering a high-growth phase, driven by rapid advancements in mRNA, siRNA, and gene-editing platforms, pushing the industry from an estimated USD 10.25 billion in 2025 toward USD 42.10 billion by 2035.
• Growing demand for scalable, high-purity nucleic acid production and the shift toward outsourced manufacturing solutions are accelerating investments in specialized CDMOs, enabling faster development timelines and improved regulatory compliance.
• With a strong CAGR of 14.5% projected through 2025–2035, the market is shaped by rising clinical pipelines, expanded bioprocessing capabilities, and increased adoption of precision therapies, positioning contract manufacturers as critical partners in next-generation therapeutic development.

McKinsey 7S Framework for the Global Nucleic Acid Therapeutics Contract Manufacturing Market

1. Strategy

• CDMOs are expanding high-capacity production platforms for mRNA, oligonucleotides, and plasmid DNA to meet accelerating therapeutic demand.
• Focus on building end-to-end service models that integrate development, GMP manufacturing, analytics, and regulatory support.
• Strategic partnerships with biotech innovators and large pharma are increasing to secure long-term supply contracts and co-development opportunities.

2. Structure

• Market leaders are restructuring operations toward modular, flexible, and single-use manufacturing facilities to scale nucleic acid production quickly.
• Global footprints are evolving with new sites in North America, Europe, and Asia to reduce supply-chain risk and meet regional regulatory expectations.
• Organizational structures emphasize cross-functional teams integrating R&D, QA/QC, and regulatory operations.

3. Systems

• Advanced digital manufacturing systems, real-time process monitoring, and automated QC are being deployed to enhance consistency in nucleic acid synthesis.
• CDMOs are adopting robust quality management systems aligned with evolving GMP guidelines for complex nucleic acid products.
• Integration of AI-driven process optimization and digital batch records improves cycle times and compliance efficiency.

4. Shared Values

• Industry-wide priorities focus on safety, precision, regulatory integrity, and scientific innovation in the production of high-purity nucleic acid therapeutics.
• Commitment to transparency, sustainability, and ethical handling of genetic materials is strengthening across manufacturing operations.
• Collaborative culture centered around patient impact and accelerated therapeutic delivery.

5. Skills

• High demand for specialized expertise in nucleic acid chemistry, lipid nanoparticle formulation, large-scale synthesis, and advanced purification techniques.
• Workforce training is increasing around GMP compliance, automation, bioinformatics, and regulatory documentation.
• CDMOs are building multidisciplinary teams capable of supporting complex nucleic acid modalities and evolving clinical pipelines.

6. Style

• Leadership approaches emphasize innovation-driven decision-making and rapid adoption of emerging manufacturing technologies.
• Management style supports cross-department collaboration to streamline development-to-manufacturing timelines.
• A customer-centric orientation prioritizes flexibility, responsiveness, and customized manufacturing solutions for biotech clients.

7. Staff

• Companies are expanding talent pools across process engineering, analytical development, and bioprocess operations to support capacity growth.
• Recruitment strategies focus on attracting skilled personnel with experience in nucleic acid therapeutics, RNA technology, and GMP manufacturing.
• Retention programs emphasize continuous learning, competitive benefits, and involvement in cutting-edge therapeutic development.

Segment for the Global Nucleic Acid Therapeutics Contract Manufacturing Market

1. By Therapeutic Type

• mRNA Therapeutics
• siRNA Therapeutics
• Antisense Oligonucleotides (ASOs)
• DNA and Plasmid DNA Therapeutics
• Aptamers
• Gene Editing Components (CRISPR gRNA, Cas-related materials)
• Viral Vector Nucleic Acid Components

2. By Manufacturing Stage

• Process Development
• Preclinical Manufacturing
• Clinical-Grade Manufacturing (Phase I–III)
• Commercial-Scale GMP Manufacturing
• Analytical Testing and Release Services
• Fill-Finish and Packaging Services

3. By Technology

• Solid-Phase Oligonucleotide Synthesis
• Enzymatic RNA/DNA Synthesis
• Lipid Nanoparticle (LNP) Formulation
• Plasmid DNA Amplification Technologies
• Large-Scale Purification Technologies (HPLC, Ion Exchange, UF/DF)
• Automated and Digital Manufacturing Platforms

4. By Application

• Oncology
• Infectious Diseases
• Rare and Genetic Disorders
• Neurological Disorders
• Cardiovascular Diseases
• Immunology and Inflammatory Conditions
• Vaccines and Preventive Therapies

5. By Service Type

• Custom Synthesis and Development Services
• GMP Manufacturing Services
• Formulation and Delivery System Development
• Quality Control and Analytical Services
• Regulatory Support and Compliance Services
• Stability Studies and Supply Chain Services

6. By Region

North America

• USA
• Canada
• Mexico

Europe

• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• South Korea
• Australia
• Rest of Asia-Pacific

Latin America

• Brazil
• Argentina
• Rest of Latin America

Middle East & Africa (MEA)

• South Africa
• UAE
• Rest of MEA

Key Players (Cumulative List – Global)

• Thermo Fisher Scientific
• Lonza Group
• Agilent Technologies, Inc
• Eurofins Scientific
• Syngene International
• ChemGenes
• BioSpring
• Ajinomoto Bio-Pharma Services
• Maravai LifeSciences (TriLink BioTechnologies)
• BioSpring GmbH